Overview

A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This study is designed to confirm if 8mg of fesoterodine is more effective in reducing overactive bladder symptoms than 4mg of fesoterodine. In addition the study is designed to assess if the higher dose reduces the overall effect of overactive bladder on the subject's daily life more than the lower dose. The study also assesses the side effects and safety of the two doses.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Fesoterodine